{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:06:41Z","timestamp":1791864401496,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Current diagnostic imaging modalities have limited ability to differentiate between malignant and benign pancreaticobiliary disease, and lack accuracy in detecting lymph node metastases. <jats:sup>18<\/jats:sup>F-Prostate-Specific Membrane Antigen (PSMA) PET\/CT is an imaging modality used for staging of prostate cancer, but has incidentally also identified PSMA-avid pancreatic lesions, histologically characterized as pancreatic ductal adenocarcinoma (PDAC). This phase I\/II study aimed to assess the feasibility of <jats:sup>18<\/jats:sup>F-PSMA PET\/CT to detect PDAC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Seventeen patients with clinically resectable PDAC underwent <jats:sup>18<\/jats:sup>F-PSMA PET\/CT prior to surgical resection. Images were analyzed both visually and (semi)quantitatively by deriving the maximum standardized uptake value (SUV<jats:sub>max<\/jats:sub>) and tumor-to-background ratio (TBR). TBR was defined as the ratio between SUV<jats:sub>max<\/jats:sub> of the primary tumor divided by SUV<jats:sub>max<\/jats:sub> of the aortic blood pool. Finally, tracer uptake on PET was correlated to tissue expression of PSMA in surgical specimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Out of 17 PSMA PET\/CT scans, 13 scans demonstrated positive PSMA tracer uptake, with a mean SUV<jats:sub>max<\/jats:sub> of 5.0\u2009\u00b1\u20091.3. The suspected primary tumor was detectable (TBR\u2009\u2265\u20092) with a mean TBR of 3.3\u2009\u00b1\u20091.3. For histologically confirmed PDAC, mean SUV<jats:sub>max<\/jats:sub> and mean TBR were 4.9\u2009\u00b1\u20091.2 and 3.3\u2009\u00b1\u20091.5, respectively. Although eight patients had histologically confirmed regional lymph node metastases and two patients had distant metastases, none of these metastases demonstrated <jats:sup>18<\/jats:sup>F-PSMA uptake. There was no correlation between <jats:sup>18<\/jats:sup>F-PSMA PET\/CT SUV<jats:sub>max<\/jats:sub> and tissue expression of PSMA in surgical specimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>\n              <jats:sup>18<\/jats:sup>F-PSMA PET\/CT was able to detect several pancreaticobiliary cancers, including PDAC. However, uptake was generally low, not specific to PDAC and no tracer uptake was observed in lymph node or distant metastases. The added value of PSMA PET in this setting appears to be limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>The trial is registered as PANSCAN-2 in the European Clinical Trials Database (EudraCT number: 2020\u2013002185-14).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s40644-025-00822-y","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T12:46:26Z","timestamp":1736858786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["18F\u2212Prostate\u2212Specific Membrane Antigen PET\/CT imaging for potentially resectable pancreatic cancer (PANSCAN\u22122): a phase I\/II study"],"prefix":"10.1186","volume":"25","author":[{"given":"Jisce R.","family":"Puik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas T.","family":"Poels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit K. J.","family":"Hooijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs C. F.","family":"Cysouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Verheij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna W.","family":"Wilmink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Giovannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Kazemier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantza Farina","family":"Sarasqueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3980-4634","authenticated-orcid":false,"given":"Rutger-Jan","family":"Swijnenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"issue":"1","key":"822_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"822_CR2","unstructured":"Cancer Statistics\u2014Cancer Stat Facts: Pancreatic Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html. Accessed 31 March 2023"},{"issue":"19","key":"822_CR3","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3748\/wjg.v24.i19.2047","volume":"24","author":"L Zhang","year":"2018","unstructured":"Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer. World J Gastroenterol. 2018;24(19):2047\u201360.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"822_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O\u2019Reilly EM, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(11):987\u20131002.","journal-title":"Ann Oncol"},{"key":"822_CR5","doi-asserted-by":"crossref","unstructured":"Treadwell JR, Zafar HM, Mitchell MD, Tipton K, Teitelbaum U, Jue J. Imaging Tests for the Diagnosis and Staging of Pancreatic Adenocarcinoma: A Meta-Analysis. Pancreas. 2016;45(6).","DOI":"10.1097\/MPA.0000000000000524"},{"issue":"1","key":"822_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.gie.2014.09.017","volume":"81","author":"U Navaneethan","year":"2015","unstructured":"Navaneethan U, Njei B, Lourdusamy V, Konjeti R, Vargo JJ, Parsi MA. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc. 2015;81(1):168\u201376.","journal-title":"Gastrointest Endosc"},{"issue":"8","key":"822_CR7","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1097\/MCG.0000000000001702","volume":"56","author":"Z Li","year":"2022","unstructured":"Li Z, Liu W, Xu X, Li P. A Meta-Analysis Comparing Endoscopic Ultrasound-guided Fine-needle Aspiration With Endoscopic Ultrasound-guided Fine-needle Biopsy. J Clin Gastroenterol. 2022;56(8):668\u201378.","journal-title":"J Clin Gastroenterol"},{"issue":"12","key":"822_CR8","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1245\/s10434-014-3810-7","volume":"21","author":"A Gerritsen","year":"2014","unstructured":"Gerritsen A, Molenaar IQ, Bollen TL, Nio CY, Dijkgraaf MG, van Santvoort HC, et al. Preoperative characteristics of patients with presumed pancreatic cancer but ultimately benign disease: a multicenter series of 344 pancreatoduodenectomies. Ann Surg Oncol. 2014;21(12):3999\u20134006.","journal-title":"Ann Surg Oncol"},{"key":"822_CR9","doi-asserted-by":"crossref","unstructured":"Li X, Wan Y, Lou J, Xu L, Shi A, Yang L, et al. Preoperative recurrence prediction in pancreatic ductal adenocarcinoma after radical resection using radiomics of diagnostic computed tomography. eClinicalMedicine. 2022;43.","DOI":"10.1016\/j.eclinm.2021.101215"},{"issue":"11","key":"822_CR10","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.hpb.2021.04.004","volume":"23","author":"S Crippa","year":"2021","unstructured":"Crippa S, Belfiori G, Bissolati M, Partelli S, Pagnanelli M, Tamburrino D, et al. Recurrence after surgical resection of pancreatic cancer: the importance of postoperative complications beyond tumor biology. HPB. 2021;23(11):1666\u201373.","journal-title":"HPB"},{"issue":"8","key":"822_CR11","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.pan.2018.09.012","volume":"18","author":"D O'Reilly","year":"2018","unstructured":"O\u2019Reilly D, Fou L, Hasler E, Hawkins J, O\u2019Connell S, Pelone F, et al. Diagnosis and management of pancreatic cancer in adults: a summary of guidelines from the UK National institute for health and care excellence. Pancreatology. 2018;18(8):962\u201370.","journal-title":"Pancreatology"},{"key":"822_CR12","unstructured":"Tempero MA, Malafa MP, Benson AB, Cardin DB, Chiorean EG. NCCN Guidelines Version 2.2023 Pancreatic Adenocarcinoma. 2023."},{"issue":"2","key":"822_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00261-017-1374-2","volume":"43","author":"R Yeh","year":"2018","unstructured":"Yeh R, Dercle L, Garg I, Wang ZJ, Hough DM, Goenka AH. The Role of 18F-FDG PET\/CT and PET\/MRI in Pancreatic Ductal Adenocarcinoma. Abdominal Radiology. 2018;43(2):415\u201334.","journal-title":"Abdominal Radiology"},{"key":"822_CR14","doi-asserted-by":"crossref","unstructured":"Sahani DV, Bonaffini PA, Catalano OA, Guimaraes AR, Blake MA. State-of-the-art PET\/CT of the pancreas: current role and emerging indications. Radiographics. 2012;32(4):1133\u201358; discussion 58\u201360.","DOI":"10.1148\/rg.324115143"},{"issue":"6","key":"822_CR15","first-page":"1030","volume":"39","author":"CG Diederichs","year":"1998","unstructured":"Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med. 1998;39(6):1030\u20133.","journal-title":"J Nucl Med"},{"issue":"12","key":"822_CR16","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1097\/RLU.0000000000004338","volume":"47","author":"Y Lu","year":"2022","unstructured":"Lu Y, Li C. Incidental findings of coexisting metastatic pancreatic cancer in patients with prostate cancer on 18 F-Prostate-specific membrane antigen PET\/CT. Clin Nucl Med. 2022;47(12):1103\u20134.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"822_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/diagnostics11010129","volume":"11","author":"S Sirtl","year":"2021","unstructured":"Sirtl S, Todica A, Ilhan H, Zorniak M, Bartenstein P, Mayerle J. Incidental finding of a PSMA-positive pancreatic cancer in a patient suffering from a metastasized PSMA-positive prostate cancer. Diagnostics. 2021;11(1):129.","journal-title":"Diagnostics"},{"issue":"2","key":"822_CR18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00259-021-05523-9","volume":"49","author":"M Bonacina","year":"2022","unstructured":"Bonacina M, Ghirardelli P, Setti L, Vavassori V, Bombardieri E. 68Ga-PSMA and 68Ga-DOTATOC PET\/CT imaging mismatch of primary pancreatic adenocarcinoma in prostate cancer patient. Eur J Nucl Med Mol Imaging. 2022;49(2):781\u20132.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"822_CR19","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/RLU.0000000000001767","volume":"42","author":"S Sahbai","year":"2017","unstructured":"Sahbai S, Rieping P, Pfannenberg C, la Foug\u00e9re C, Reimold M. pancreatic ductal adenocarcinoma with high radiotracer uptake in 68Ga-prostate-specific membrane antigen PET\/CT. Clin Nucl Med. 2017;42(9):717\u20138.","journal-title":"Clin Nucl Med"},{"issue":"13","key":"822_CR20","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","volume":"27","author":"MJ Morris","year":"2021","unstructured":"Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, et al. Diagnostic Performance of 18F-DCFPyL-PET\/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III Multicenter Study. Clin Cancer Res. 2021;27(13):3674\u201382.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"822_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer\u20142020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology. 2021;79(2):243\u201362.","journal-title":"European Urology."},{"issue":"1","key":"822_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","volume":"1","author":"GL Wright","year":"1995","unstructured":"Wright GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1(1):18\u201328.","journal-title":"Urol Oncol"},{"issue":"11","key":"822_CR23","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","volume":"82","author":"DG Bostwick","year":"1998","unstructured":"Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma. Cancer. 1998;82(11):2256\u201361.","journal-title":"Cancer"},{"issue":"1","key":"822_CR24","doi-asserted-by":"publisher","first-page":"16211","DOI":"10.1038\/s41598-020-73242-6","volume":"10","author":"FA Vuijk","year":"2020","unstructured":"Vuijk FA, de Muynck LDAN, Franken LC, Busch OR, Wilmink JW, Besselink MG, et al. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment. Sci Rep. 2020;10(1):16211.","journal-title":"Sci Rep"},{"issue":"3","key":"822_CR25","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s12032-014-0857-z","volume":"31","author":"H Ren","year":"2014","unstructured":"Ren H, Zhang H, Wang X, Liu J, Yuan Z, Hao J. Prostate-specific membrane antigen as a marker of pancreatic cancer cells. Med Oncol. 2014;31(3):857.","journal-title":"Med Oncol"},{"key":"822_CR26","doi-asserted-by":"publisher","first-page":"2847303","DOI":"10.1155\/2017\/2847303","volume":"2017","author":"K Stock","year":"2017","unstructured":"Stock K, Steinestel K, Wiesch R, Mikesch JH, Hansmeier A, Trautmann M, et al. Neovascular Prostate-Specific Membrane Antigen Expression Is Associated with Improved Overall Survival under Palliative Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. Biomed Res Int. 2017;2017:2847303.","journal-title":"Biomed Res Int"},{"key":"822_CR27","unstructured":"PANSCAN-2 EEA CTA. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002185-14\/NL. Accessed 31 August 2023"},{"issue":"4","key":"822_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","volume":"17","author":"Z Szabo","year":"2015","unstructured":"Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol. 2015;17(4):565\u201374.","journal-title":"Mol Imaging Biol"},{"issue":"5","key":"822_CR29","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48(5):1626\u201338.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"4","key":"822_CR30","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1007\/s00330-020-07318-2","volume":"31","author":"VS Krishnaraju","year":"2021","unstructured":"Krishnaraju VS, Kumar R, Mittal BR, Sharma V, Singh H, Nada R, et al. Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET\/CT as a new diagnostic avenue. Eur Radiol. 2021;31(4):2199\u2013208.","journal-title":"Eur Radiol"},{"key":"822_CR31","doi-asserted-by":"crossref","unstructured":"Vuijk FA, Kleiburg F, Noortman WA, Heijmen L, Feshtali Shahbazi S, van Velden FHP, et al. Prostate-Specific Membrane Antigen Targeted Pet\/CT Imaging in Patients with Colon, Gastric and Pancreatic Cancer. Cancers (Basel). 2022;14(24).","DOI":"10.3390\/cancers14246209"},{"issue":"3","key":"822_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.euo.2022.03.004","volume":"5","author":"L Evangelista","year":"2022","unstructured":"Evangelista L, Maurer T, van der Poel H, Alongi F, Kunikowska J, Laudicella R, et al. [68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography\/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. Eur Urol Oncol. 2022;5(3):273\u201382.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"822_CR33","first-page":"44","volume":"11","author":"H Marquis","year":"2023","unstructured":"Marquis H, Willowson KP, Bailey DL. Partial volume effect in SPECT & PET imaging and impact on radionuclide dosimetry estimates. Asia Ocean J Nucl Med Biol. 2023;11(1):44\u201354.","journal-title":"Asia Ocean J Nucl Med Biol"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00822-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-025-00822-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-025-00822-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:35:12Z","timestamp":1736901312000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-025-00822-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["822"],"URL":"https:\/\/doi.org\/10.1186\/s40644-025-00822-y","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"7 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The PANSCAN-2 study was a non-blinded, prospective phase I\/II study that was conducted at the Amsterdam UMC between 2021 and 2023. The study protocol and study-related procedures were designed and conducted in full compliance with the ethical guidelines of the Declaration of Helsinki and International Conference on Harmonization (ICH) guidelines on Good Clinical Practice, as well as the Dutch national and local regulations. The study protocol was approved by the Medical Ethical Board of the Amsterdam UMC, location VUmc (NL73356.029.20). The trial is registered as PANSCAN-2 in the European Clinical Trials Database (EudraCT number: 2020\u2013002185-14). Before study participation, written informed consent was obtained from each individual patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from each individual patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}